Other languages Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Market Closed - Nasdaq Other stock markets 02:00:00 21/05/2024 am IST			5-day change	1st Jan Change
1.5 ^USD	-3.25%		+3.78%	-19.38%

22/04	Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	MT
12/04	Top Premarket Decliners	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	22/04
Top Premarket Decliners	12/04
Top Midday Gainers	10/04
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	10/04
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Top Premarket Decliners	04/03
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	01/03
US Futures Remain Flat as Investors Await Raft of Economic Data	01/03
Top Midday Gainers	29/02
Adial Pharmaceuticals Secures US Patent Allowance for AD04, Genetic Diagnostic Combination	13/02
Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office	13/02
Adial Pharmaceuticals Appoints Tony Goodmans as Chief Operating Officer	18/01
Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer	18/01
Top Premarket Gainers	30/11
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Adial Pharmaceuticals Awarded Patent Combining Use of Genetic Diagnostic With AD04 to Treat Alcohol, Drug Dependence	19/23/19
Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence	19/23/19
Adial Pharmaceuticals, Inc. Announces Board Changes	22/23/22
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Other languages

Filters